Insmed Incorporated INSM shares are up during Monday’s session following the announcement of positive topline results from ...

Truist has a ‘Buy’ rating on the shares with a price target of $205, representing a potential upside of about 51% from Friday ...

Insmed said Monday that the addition of its drug Arikayce to a standard treatment for patients with a rare bacterial lung ...

Shares of Insmed climbed after the company disclosed what it called positive topline results from a late-stage study of its treatment for certain lung infections. The stock rose 10%, to $150.02, in ...

Using a virus to kill a bacterium may seem like going backward in medicine and harkens back to the early 20 th century when Julius Wagner-Juarreg used malaria to cure neurosyphilis (a feat that won ...

DENVER — (MAY 13, 2022) For the first time, researchers have successfully used bacteriophages – viruses that kill bacteria – to treat an antibiotic-resistant mycobacterial lung infection, clearing the ...

More people around the world have nontuberculous mycobacteria (NTM) infections now than in the past. The infection most often comes from a type of NTM known as mycobacterium avium complex (MAC). MAC ...

For the first time, researchers have successfully used bacteriophages – viruses that kill bacteria – to treat an antibiotic-resistant mycobacterial lung infection, clearing the way for a young ...

DRESHER, PA. (WPVI) -- We need bacteria to digest food and absorb nutrients. However, when a bacteria commonly found in soil and water gets into our lungs, it can cause trouble, in the form of a MAC ...

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Insmed Incorporated (Nasdaq GS:INSM) today reported results from the Company’s phase 2 clinical trial of ARIKAYCE TM, or liposomal amikacin for inhalation, ...

Mycobacterium avium complex (MAC), a type of nontuberculous mycobacteria (NTM), lives all around us. You’ll find these germs in dirt, dust, and drinking water. They’re also common in natural sources ...